Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late‐life dementia
- 1 October 2006
- journal article
- editorial
- Published by Wiley in Alzheimer's & Dementia
- Vol. 2 (4) , 287-293
- https://doi.org/10.1016/j.jalz.2006.05.2347
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Frontotemporal dementia: Clinicopathological correlationsAnnals of Neurology, 2006
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humansAnnals of Neurology, 2006
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyPublished by Elsevier ,2006
- The Role of Biomarkers in Clinical Trials for Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2006
- Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's diseaseAnnals of Neurology, 2005
- MRI and CSF studies in the early diagnosis of Alzheimer's diseaseJournal of Internal Medicine, 2004
- Biological markers for therapeutic trials in Alzheimer’s diseaseNeurobiology of Aging, 2003
- Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairmentActa Neurologica Scandinavica, 2003
- Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's diseaseAnnals of Neurology, 2002
- Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's diseaseAnnals of Neurology, 1998